RGA Investment Advisors released its Q2 2025 investor letter, highlighting market volatility and global trade impacts. The letter includes top 5 holdings for 2025. CRISPR Therapeutics AG (CRSP) was featured, with a one-month return of -8.57% and closing at $59.73 per share on August 15, 2025.

In the investor letter, RGA Investment Advisors discussed CRISPR Therapeutics AG (CRSP), mentioning the commercial approval of Casgevy and the stock’s performance during the April crash. Despite a spring collapse of nearly 30%, the company’s substantial cash balance was noted for resilience. CRSP soared 18% after $51-million insider trading.

CRISPR Therapeutics AG (CRSP) was not among the 30 most popular stocks among hedge funds in Q1. While acknowledging its investment potential, RGA prefers AI stocks for greater upside potential and lower downside risk. Check out other articles covering CRSP and investor letters from hedge funds for more insights.

For more information on the best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money, visit Insider Monkey. Note: This article is originally published at Insider Monkey and has no disclosed affiliations.

Read more at Yahoo Finance: What Makes Crispr Therapeutics Ag (CRSP) a Good Buy?